Nurix Therapeutics: Positive Results from Ongoing Clinical Trial of NX-5948

Nurix Therapeutics in the NEWS

On June 16, 2024, Nurix Therapeutics (NRIX) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton’s tyrosine kinase (BTK), being evaluated in an ongoing Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies, including CLL and non-Hodgkin lymphoma (NHL

This content is for paid subscribers.
Please click here to subscribe or here to log in.